Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
AADI Stock Forecast 2026-2027
$1.99
Current Price
$94.89M
Market Cap
Buy 0
Hold 2
Sell 0
Wall St Analyst Ratings
Distance to AADI Price Targets
+0.5%
To High Target of $2.00
+0.5%
To Median Target of $2.00
+0.5%
To Low Target of $2.00
AADI Price Momentum
0.0%
1 Week Change
0.0%
1 Month Change
0.0%
1 Year Change
0.0%
Year-to-Date Change
-47.8%
From 52W High of $3.81
+64.5%
From 52W Low of $1.21
📊 TOP ANALYST CALLS
Did AADI Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Aadi Bioscience is one of their latest high-conviction picks.
Latest AADI Stock Price Targets & Analyst Predictions
Based on our analysis of 4 Wall Street analysts, AADI has a neutral consensus with a median price target of $2.00 (ranging from $2.00 to $2.00). The overall analyst rating is Buy (6.0/10). Currently trading at $1.99, the median forecast implies a 0.5% upside. This outlook is supported by 0 Buy, 2 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
AADI Analyst Ratings
0
Buy
2
Hold
0
Sell
AADI Price Target Range
Low
$2.00
Average
$2.00
High
$2.00
Current: $1.99
Latest AADI Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for AADI.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Aug 27, 2024 | Piper Sandler | Joseph Catanzaro | Neutral | Downgrade | $1.75 |
| Aug 21, 2024 | TD Cowen | Boris Peaker | Hold | Downgrade | $N/A |
| Aug 21, 2024 | HC Wainwright & Co. | Robert Burns | Neutral | Reiterates | $N/A |
| May 14, 2024 | HC Wainwright & Co. | Robert Burns | Neutral | Reiterates | $N/A |
| Dec 15, 2023 | HC Wainwright & Co. | Robert Burns | Neutral | Downgrade | $N/A |
| Dec 15, 2023 | Piper Sandler | Joseph Catanzaro | Overweight | Maintains | $5.00 |
| Nov 13, 2023 | HC Wainwright & Co. | Robert Burns | Buy | Maintains | $36.00 |
| Aug 10, 2023 | HC Wainwright & Co. | Robert Burns | Buy | Reiterates | $45.00 |
| Jun 8, 2023 | HC Wainwright & Co. | Robert Burns | Buy | Reiterates | $45.00 |
| May 17, 2023 | HC Wainwright & Co. | Robert Burns | Buy | Reiterates | $45.00 |
| Mar 29, 2023 | HC Wainwright & Co. | Robert Burns | Buy | Maintains | $45.00 |
| Apr 11, 2022 | HC Wainwright & Co. | Robert Burns | Buy | Maintains | $48.00 |
| Jan 11, 2022 | Jefferies | Buy | Initiates | $N/A | |
| Nov 24, 2021 | HC Wainwright & Co. | Robert Burns | Buy | Maintains | $49.00 |
| Oct 1, 2021 | Cowen & Co. | Outperform | Initiates | $N/A | |
| Sep 14, 2021 | Ladenburg Thalmann | Buy | Initiates | $N/A | |
| Sep 8, 2021 | Piper Sandler | Overweight | Initiates | $N/A | |
| Aug 30, 2021 | HC Wainwright & Co. | Robert Burns | Buy | Maintains | $47.00 |
Aadi Bioscience Inc. (AADI) Competitors
The following stocks are similar to Aadi Bioscience based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
AADI
Aadi Bioscience
mkt cap
94.89M
Aadi Bioscience Inc. (AADI) Financial Data
Valuation Metrics
Market Cap
$94.89M
Enterprise Value
$-11,145,846
P/E Ratio
N/A
PEG Ratio
-2.0x
Price/Sales
3.8x
Growth & Margins
Revenue Growth (YoY)
+21.0%
Gross Margin
+89.4%
Operating Margin
-149.4%
Net Margin
-246.1%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+127.7%
Current Ratio
4.9x
Debt/Equity
1.4x
ROE
-66.0%
ROA
-35.3%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Aadi Bioscience Inc. (AADI) Business Model
About Aadi Bioscience Inc.
What They Do
Develops precision therapies for cancer treatment.
Business Model
Aadi Bioscience generates revenue by developing and commercializing targeted therapies that address specific genetic markers in cancer treatment. The focus on precision medicine allows the company to create customized therapies that enhance treatment efficacy and safety, catering to the unique needs of individual patients.
Additional Information
The company's innovative approach positions it at the forefront of the biopharmaceutical industry, as it addresses significant unmet medical needs in oncology. Aadi Bioscience aims to transform the treatment landscape for chronic diseases by prioritizing personalized healthcare solutions.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
40
CEO
Dr. David J. Lennon Ph.D.
Country
United States
IPO Year
2017
Website
ir.whitehawktx.comAadi Bioscience Inc. (AADI) Latest News & Analysis
Latest News
Quick Summary
Whitehawk Therapeutics, formerly Aadi Bioscience, will trade on Nasdaq as WHWK starting March 19, 2025. The company aims to enhance its ADC portfolio and expects funding to last into 2028.
Why It Matters
The name change to Whitehawk Therapeutics highlights a strategic shift towards advanced ADC therapies, potentially signaling growth and innovation, which can influence investor sentiment and stock performance.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Aadi Bioscience, Inc. (Nasdaq: AADI) will host a webcast on March 19, 2025, to discuss Q4 and full-year 2024 financial results and recent company updates.
Why It Matters
Aadi Bioscience's upcoming webcast on financial results and corporate updates could influence stock performance, signaling operational health and future growth potential to investors.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Aadi Bioscience (AADI) is expected to report earnings that may surpass estimates, driven by strong key factors ahead of its upcoming financial report.
Why It Matters
Aadi Bioscience's potential for an earnings beat may boost stock prices, indicating strong performance and investor confidence, which can attract more investment and trading activity.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Aadi Bioscience, Inc. (NASDAQ: AADI) announced that stockholders approved all proposals at the Special Meeting held on February 28, 2025.
Why It Matters
Approval of all proposals at Aadi Bioscience's stockholder meeting may signal strong governance and strategic alignment, potentially boosting investor confidence and impacting stock performance.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Aadi Bioscience, Inc. has completed its private placement, aimed at advancing its oncology therapeutics using advanced technologies for cancer treatment.
Why It Matters
Aadi Bioscience's private placement indicates financial backing for its oncology initiatives, potentially enhancing growth prospects and impacting stock performance.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Aadi Bioscience, Inc. (NASDAQ: AADI) will present at the TD Cowen 45th Annual Healthcare Conference in Boston, March 3-5, 2025.
Why It Matters
Aadi Bioscience's presentation at a major healthcare conference may signal potential developments or partnerships, influencing investor sentiment and stock performance.
Source: PRNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About AADI Stock
What is Aadi Bioscience Inc.'s (AADI) stock forecast for 2027?
Based on our analysis of 4 Wall Street analysts, Aadi Bioscience Inc. (AADI) has a median price target of $2.00. The highest price target is $2.00 and the lowest is $2.00.
Is AADI stock a good investment in 2027?
According to current analyst ratings, AADI has 0 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.99. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for AADI stock?
Wall Street analysts predict AADI stock could reach $2.00 in the next 12 months. This represents a 0.5% increase from the current price of $1.99. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Aadi Bioscience Inc.'s business model?
Aadi Bioscience generates revenue by developing and commercializing targeted therapies that address specific genetic markers in cancer treatment. The focus on precision medicine allows the company to create customized therapies that enhance treatment efficacy and safety, catering to the unique needs of individual patients.
What is the highest forecasted price for AADI Aadi Bioscience Inc.?
The highest price target for AADI is $2.00 from at , which represents a 0.5% increase from the current price of $1.99.
What is the lowest forecasted price for AADI Aadi Bioscience Inc.?
The lowest price target for AADI is $2.00 from at , which represents a 0.5% increase from the current price of $1.99.
What is the overall AADI consensus from analysts for Aadi Bioscience Inc.?
The overall analyst consensus for AADI is neutral. Out of 4 Wall Street analysts, 0 rate it as Buy, 2 as Hold, and 0 as Sell, with a median price target of $2.00.
How accurate are AADI stock price projections?
Stock price projections, including those for Aadi Bioscience Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 16, 2026 12:01 AM UTC